Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 zolbetuximab monotherapy or zolbetuximab plus mFOLFOX6 in CLDN18.2-positive advanced gastric/GEJ adenocarcinoma
2017-002566-50Phase 2Active
- Sponsor
- Astellas Pharma
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Astellas Pharma. Primary endpoint: Objective response rate of zolbetuximab monotherapy by independent review. Started Apr 2018; status: active.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-002566-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002566-50.